Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)Tricia R. Cottrell, Janis M. Taube, Elizabeth D. Thompson et al.|Annals of Oncology|2018Cited by 588
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung CancerValsamo Anagnostou, Victor E. Velculescu, Patrick M. Forde et al.|Cancer Research|2018Cited by 313
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic SarcomasNatasha Rekhtman, William D. Travis, Andrew J. Plodkowski et al.|Journal of Thoracic Oncology|2019Cited by 307
The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung CancerAdam J. Schoenfeld, Gregory J. Riely, Chai Bandlamudi et al.|Clinical Cancer Research|2020Cited by 281
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerDanish Memon, Matthew D. Hellmann, Adam J. Schoenfeld et al.|Cancer Cell|2024Cited by 177